S D Reed

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint Inpatient costs, length of stay, and mortality for cerebrovascular events in community hospitals
    S D Reed
    Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, USA
    Neurology 57:305-14. 2001
  2. ncbi request reprint A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial results
    Shelby D Reed
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, USA
    Med Decis Making 23:252-64. 2003
  3. ncbi request reprint Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals
    S D Reed
    Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, Department of Neurology, School of Medicine, University of Washington, Seattle, Washington, USA
    Stroke 32:1832-40. 2001
  4. ncbi request reprint Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia
    Shelby D Reed
    Center for Clinical and Genetic Economics, USA
    Infect Control Hosp Epidemiol 26:175-83. 2005
  5. ncbi request reprint Conducting economic evaluations alongside multinational clinical trials: toward a research consensus
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke University Medical Centre, Durham, NC, USA
    Am Heart J 149:434-43. 2005
  6. ncbi request reprint Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis
    John J Engemann
    Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    Infect Control Hosp Epidemiol 26:534-9. 2005
  7. ncbi request reprint Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT)
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Am Heart J 150:323-9. 2005
  8. ncbi request reprint Staphylococcus aureus bacteremia in patients with prosthetic devices: costs and outcomes
    Vivian H Chu
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Am J Med 118:1416. 2005
  9. ncbi request reprint Cost savings with implementation of PNA FISH testing for identification of Candida albicans in blood cultures
    Barbara D Alexander
    Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Box 3035, Durham, NC 27710, USA
    Diagn Microbiol Infect Dis 54:277-82. 2006
  10. ncbi request reprint Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Pharmacoeconomics 24:479-94. 2006

Detail Information

Publications34

  1. ncbi request reprint Inpatient costs, length of stay, and mortality for cerebrovascular events in community hospitals
    S D Reed
    Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, USA
    Neurology 57:305-14. 2001
    ....
  2. ncbi request reprint A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial results
    Shelby D Reed
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, USA
    Med Decis Making 23:252-64. 2003
    ..Among patients undergoing coronary stenting, the cost-effectiveness ratio of the addition of abciximab was at or below the $50,000 per life year saved threshold in 66.0% of the simulations...
  3. ncbi request reprint Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals
    S D Reed
    Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, Department of Neurology, School of Medicine, University of Washington, Seattle, Washington, USA
    Stroke 32:1832-40. 2001
    ..The likelihood of receiving IV tPA varies by race, age, disease severity, and possibly gender. These factors may influence mortality rates...
  4. ncbi request reprint Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia
    Shelby D Reed
    Center for Clinical and Genetic Economics, USA
    Infect Control Hosp Epidemiol 26:175-83. 2005
    ..We compared costs and outcomes of methicillin resistance in patients with S. aureus bacteremia and a single chronic condition...
  5. ncbi request reprint Conducting economic evaluations alongside multinational clinical trials: toward a research consensus
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke University Medical Centre, Durham, NC, USA
    Am Heart J 149:434-43. 2005
    ..Delineation of the various approaches to multinational economic evaluation may assist researchers, peer reviewers, journal editors, and decision makers in evaluating the strengths and limitations of particular studies...
  6. ncbi request reprint Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis
    John J Engemann
    Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    Infect Control Hosp Epidemiol 26:534-9. 2005
    ..To examine the clinical outcomes and costs associated with Staphylococcus aureus bacteremia among hemodialysis-dependent patients...
  7. ncbi request reprint Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT)
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Am Heart J 150:323-9. 2005
    ..We conducted a prospective economic evaluation to compare within-trial resource use, costs, and quality of life in patients receiving valsartan, captopril, or both after MI...
  8. ncbi request reprint Staphylococcus aureus bacteremia in patients with prosthetic devices: costs and outcomes
    Vivian H Chu
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Am J Med 118:1416. 2005
    ..aureus bacteremia on patients with prosthetic devices. This investigation sought to define the clinical outcome, health care resource use, and infection-associated costs of S. aureus bacteremia in patients with prostheses...
  9. ncbi request reprint Cost savings with implementation of PNA FISH testing for identification of Candida albicans in blood cultures
    Barbara D Alexander
    Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Box 3035, Durham, NC 27710, USA
    Diagn Microbiol Infect Dis 54:277-82. 2006
    ..Incorporating the C. albicans PNA FISH test as part of the initial identification algorithm for yeasts recovered from blood can result in substantial savings for hospitals...
  10. ncbi request reprint Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Pharmacoeconomics 24:479-94. 2006
    ..We sought to compare resource use, costs and clinical outcomes between treatment groups and report the results using a cost-consequences framework...
  11. ncbi request reprint Analytic considerations in economic evaluations of multinational cardiovascular clinical trials
    Frank M Torti
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Value Health 9:281-91. 2006
    ..Although recommendations for conducting economic evaluations have been widely disseminated, relatively little guidance has been given for conducting economic evaluations alongside clinical trials, particularly multinational trials...
  12. ncbi request reprint Financial implications of a model heart failure disease management program for providers, hospital, healthcare systems, and payer perspectives
    David J Whellan
    Jefferson Medical College, Philadelphia, Pennsylvania, USA
    Am J Cardiol 99:256-60. 2007
    ....
  13. ncbi request reprint Relationship between clinical outcomes and vascular access type among hemodialysis patients with Staphylococcus aureus bacteremia
    Jula K Inrig
    Department of Medicine, Division of Nephrology, Duke University Medical Center, Durham, NC 27705, USA
    Clin J Am Soc Nephrol 1:518-24. 2006
    ..Twelve-week mortality and costs that are associated with an episode of SAB are high in hemodialysis patients, regardless of vascular access type. Efforts should focus on the prevention of SAB in this high-risk group...
  14. pmc Economic evaluation of propofol and lorazepam for critically ill patients undergoing mechanical ventilation
    Christopher E Cox
    Duke University, Chapel Hill, NC, USA
    Crit Care Med 36:706-14. 2008
    ..Therefore, we aimed to determine the cost-effectiveness of the most commonly used sedatives prescribed for mechanically ventilated critically ill patients...
  15. ncbi request reprint Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Am J Clin Oncol 28:8-16. 2005
    ..There were no significant cost differences between patients receiving zoledronic acid and those receiving pamidronate...
  16. ncbi request reprint Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia
    Shelby D Reed
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina 27715, USA
    Pharmacoeconomics 26:435-46. 2008
    ..For trials in which participants are followed beyond the main study period to assess long-term outcomes, economic evaluations conducted using short-term data should be systematically updated to reflect new information...
  17. ncbi request reprint The economic burden of allergic rhinitis: a critical evaluation of the literature
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Pharmacoeconomics 22:345-61. 2004
    ....
  18. ncbi request reprint Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)
    Shelby D Reed
    Center for Clinical and Genetic Economics, Durham, NC, USA
    Am Heart J 148:122-8. 2004
    ..We sought to compare resource use, costs, and health outcomes among patients taking prescribed therapy for heart failure and randomly assigned to receive valsartan or placebo...
  19. ncbi request reprint Economic issues and antibiotic resistance in the community
    Shelby D Reed
    Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, WA, USA
    Ann Pharmacother 36:148-54. 2002
    ..Multiple economic factors, at the level of physicians, patients, healthcare organizations, and pharmaceutical companies, foster poor antibiotic use...
  20. pmc Parents' reported preference scores for childhood atopic dermatitis disease states
    Joelle Y Friedman
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA
    BMC Pediatr 4:21. 2004
    ....
  21. ncbi request reprint Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia
    Kevin J Anstrom
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 101:2584-92. 2004
    ..The authors estimated survival among patients with chronic myeloid leukemia for a cost-effectiveness analysis of imatinib versus interferon-alpha plus low-dose cytarabine (IFN+LDAC)...
  22. ncbi request reprint Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 101:2574-83. 2004
    ..In the current study, the authors estimated the incremental cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine (IFN+LDAC) as first-line therapy for these patients...
  23. ncbi request reprint Comparison of hospital costing methods in an economic evaluation of a multinational clinical trial
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 17715, USA
    Int J Technol Assess Health Care 19:396-406. 2003
    ..To develop and evaluate strategies for estimating hospitalization costs in multinational clinical trials...
  24. ncbi request reprint Characteristics of nontraumatic subarachnoid hemorrhage in the United States in 2003
    Alisa M Shea
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina 27715, USA
    Neurosurgery 61:1131-7; discussion 1137-8. 2007
    ..We examined the epidemiology and in-hospital outcomes of nontraumatic SAH in the United States...
  25. pmc Economic implications of potential changes to regulatory and reimbursement policies for medical devices
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
    J Gen Intern Med 23:50-6. 2008
    ..To evaluate the impact of regulatory scenarios on the financial viability of medical device companies...
  26. ncbi request reprint Treatment patterns and costs associated with sessile colorectal polyps
    Jane E Onken
    Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Am J Gastroenterol 97:2896-901. 2002
    ....
  27. ncbi request reprint Direct costs of allergic rhinitis in the United States: estimates from the 1996 Medical Expenditure Panel Survey
    Amy W Law
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Durham, NC 27715, USA
    J Allergy Clin Immunol 111:296-300. 2003
    ..Previous estimates of the cost of allergic rhinitis predate the substantial increase in the use of second-generation antihistamines and intranasal corticosteroids...
  28. ncbi request reprint Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 152:500-8. 2006
    ..By examining this international trial population of high-risk patients, we sought to determine geographic variations in the use of 3 key treatments for MI...
  29. ncbi request reprint The cost of inefficiency in US hospitals, 1985-1997
    Bimal R Shah
    Stanford University Hospitals, USA
    J Health Care Finance 30:1-9. 2003
    ..Hospital overhead costs are increasing faster than would be expected if efficiency were the primary goal of hospital management...
  30. ncbi request reprint Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center Durham, North Carolina, USA
    J Urol 171:1537-42. 2004
    ..We estimated the cost-effectiveness of zoledronic acid vs placebo for decreasing skeletal complications in men with prostate cancer...
  31. ncbi request reprint Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Curr Med Res Opin 21:1527-33. 2005
    ..To examine associations between early hemoglobin response and alternative measures of efficacy following treatment with an erythropoietic agent for chemotherapy-related anemia...
  32. ncbi request reprint Impact of disease severity and gastrointestinal side effects on the health state preferences of patients with osteoarthritis
    Jane Chang
    Duke University Medical Center, Durham, NC 27715, USA
    Arthritis Rheum 52:2366-75. 2005
    ..To describe the health state preferences of patients with osteoarthritis (OA) according to the level of pain and disability and the extent of gastrointestinal side effects from nonsteroidal antiinflammatory drugs (NSAIDs)...
  33. ncbi request reprint A multinational review of recent trends and reports in dementia caregiver burden
    Frank M Torti
    University of North Carolina at Chapel Hill School of Medicine, USA
    Alzheimer Dis Assoc Disord 18:99-109. 2004
    ..Future interventions to reduce caregiver burden must consider these differences, identify patients and caregivers at greatest risk, and develop targeted programs that combine aspects of a number of interventional strategies...
  34. ncbi request reprint Economic evaluation of everolimus vs. azathioprine at one year after de novo heart transplantation
    Jasmina I Radeva
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Durham, NC 27715, USA
    Clin Transplant 19:122-9. 2005
    ..We compared within-trial costs and resource use over 1 yr of follow-up in de novo heart transplant patients randomized to everolimus 1.5 mg/d (n = 209), everolimus 3.0 mg/d (n = 211), or azathioprine (n = 214)...